Literature DB >> 10824047

Trends in diagnostic and therapeutic criteria in Graves' disease in the last 10 years.

F Escobar-Jiménez1, M L Férnandez-Soto, V Luna-López, M Quesada-Charneco, D Glinoer.   

Abstract

A questionnaire describing a typical clinical case of Graves' disease and 10 variations on it was mailed to 70 Spanish units of endocrinology with the aim of assessing the new diagnostic and therapeutic trends for hyperthyroidism caused by Graves' disease in Spain and to compare the results obtained from previous studies carried out in Europe and Spain 10 years previously. Responses indicated that thyrotrophin (98%) and free thyroxine (88%) were the most used tests in the in vitro diagnosis of Graves' disease with a significant decrease in the use of total thyroxine, total triiodothyronine, and thyroglobulin in comparison with the surveys conducted 10 years previously in Europe and Spain. The presence of antibodies against the thyrotrophin receptor was the most frequently used immune marker in the diagnosis (78%) and the new use of antithyroperoxidase antibodies (36%) in diagnosis is noteworthy. Antithyroid drugs remain the treatment of choice (98%). Surgery was used mainly for large size goitres (33%) and radioiodine for recurrences after medical (61%) or surgical (80%) treatment. In conclusion, the responses obtained from this questionnaire provide insight into current specialist diagnostic and therapeutic practices with respect to Graves' disease and which could be of value to non-specialist units of endocrinology.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10824047      PMCID: PMC1741609          DOI: 10.1136/pmj.76.896.340

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  14 in total

Review 1.  Clinical review 12: The use and misuse of the sensitive thyrotropin assays.

Authors:  J T Nicoloff; C A Spencer
Journal:  J Clin Endocrinol Metab       Date:  1990-09       Impact factor: 5.958

2.  Immunogenetic markers in patients with Graves' disease.

Authors:  E Schifferdecker; P Kühnl; K Schöffling; B Manfras; G Holzberger; W Spielmann; B O Böhm
Journal:  Klin Wochenschr       Date:  1991-04-04

3.  Differences and similarities in the diagnosis and treatment of Graves' disease in Europe, Japan, and the United States.

Authors:  L Wartofsky; D Glinoer; B Solomon; S Nagataki; R Lagasse; Y Nagayama; M Izumi
Journal:  Thyroid       Date:  1991       Impact factor: 6.568

4.  Current trends in the management of Graves' disease.

Authors:  B Solomon; D Glinoer; R Lagasse; L Wartofsky
Journal:  J Clin Endocrinol Metab       Date:  1990-06       Impact factor: 5.958

Review 5.  Controversies in the management of Graves' disease.

Authors:  N J Leech; C M Dayan
Journal:  Clin Endocrinol (Oxf)       Date:  1998-09       Impact factor: 3.478

6.  The management of hyperthyroidism due to Graves' disease in Europe in 1986. Results of an international survey.

Authors:  D Glinoer; D Hesch; R Lagasse; P Laurberg
Journal:  Acta Endocrinol Suppl (Copenh)       Date:  1987

7.  The management of hyperthyroidism due to Graves' disease in Japan in 1988. The Japan Thyroid Association.

Authors:  Y Nagayama; M Izumi; S Nagataki
Journal:  Endocrinol Jpn       Date:  1989-04

8.  Long-term propranolol therapy in pregnancy: maternal and fetal outcome.

Authors:  S C Pruyn; J P Phelan; G C Buchanan
Journal:  Am J Obstet Gynecol       Date:  1979-10-15       Impact factor: 8.661

9.  [Long-term evolution of immunologic and thyroid function in Graves disease according different therapeutic options].

Authors:  M M Campos Pastor; M L Fernández Soto; F Escobar-Jiménez; F Barredo Acedo; M Ruiz de Almodóvar
Journal:  Med Clin (Barc)       Date:  1994-04-02       Impact factor: 1.725

10.  Diagnosis and treatment of thyrotoxicosis in childhood. A European questionnaire study.

Authors:  H Perrild; A Grüters-Kieslich; U Feldt-Rasmussen; D Grant; E Martino; L Kayser; F Delange
Journal:  Eur J Endocrinol       Date:  1994-11       Impact factor: 6.664

View more
  5 in total

1.  Safety of long-term antithyroid drug treatment? A systematic review.

Authors:  F Azizi; R Malboosbaf
Journal:  J Endocrinol Invest       Date:  2019-05-27       Impact factor: 4.256

2.  Long-term follow-up of patients with hyperthyroidism due to Graves' disease treated with methimazole. Comparison of usual treatment schedule with drug discontinuation vs continuous treatment with low methimazole doses: a retrospective study.

Authors:  E Mazza; M Carlini; D Flecchia; A Blatto; O Zuccarini; S Gamba; S Beninati; M Messina
Journal:  J Endocrinol Invest       Date:  2008-10       Impact factor: 4.256

3.  Long-Term Antithyroid Drug Treatment of Graves' Disease in Children and Adolescents: A 20-Year Single-Center Experience.

Authors:  Ari Song; Su Jin Kim; Min-Sun Kim; Jiyeon Kim; Insung Kim; Ga Young Bae; Eunseop Seo; Young Seok Cho; Joon Young Choi; Sung Yoon Cho; Dong-Kyu Jin
Journal:  Front Endocrinol (Lausanne)       Date:  2021-06-14       Impact factor: 5.555

4.  Co-occurrence of autoimmune thyroid disease in a multiple sclerosis cohort.

Authors:  J S Sloka; Pryse-W E M Phillips; M Stefanelli; C Joyce
Journal:  J Autoimmune Dis       Date:  2005-11-09

5.  Treatment of patients with Graves' disease in Sweden compared to international surveys of an 'index patient'.

Authors:  Gabriel Sjölin; Kristina Byström; Mats Holmberg; Ove Törring; Selwan Khamisi; Jan Calissendorff; Mikael Lantz; Bengt Hallengren; Helena Filipsson Nyström; Tereza Planck; Göran Wallin
Journal:  Endocrinol Diabetes Metab       Date:  2021-03-16
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.